Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

October 21, 2019

Verseau launches with $50m to develop first-in-class macrophage-targeted immunotherapies

Verseau Therapeutics, Inc. (“Verseau”) launched with $50 million in financing from 20/20 HealthCare Partners, 3SBio, Alexandria Venture Investments, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research and Yonghua Capital.

Verseau launches with $50m to develop first-in-class macrophage-targeted immunotherapies